Orexo appoints Robin Wright as new EVP Head of Finance and Strategy

Orexo appoints Robin Wright as new EVP Head of Finance and Strategy

Uppsala, Sweden, August 10, 2010 - Orexo AB (STO: ORX) appoints Robin
Wright as EVP Head of Finance replacing Claes Wenthzel who, after five
years in the Group, has decided  to leave the company for other
assignments. Robin Wright will maintain his current responsibilities of
Business Development and he will commence his new role August 20, 2010.

Torbjörn Bjerke, President and CEO, comments: “Robin Wright has, with
his extensive experience, the right set of skills to take on the role as
EVP Head of Finance. He has many years of experience from corporate
finance within pharma from leading investment banks. In addition, Robin
Wright has been group finance director for a private equity fund and he
has board experience from NASDAQ-listed Hibernia Food plc. I would also
like to thank Claes Wenthzel for his years with Orexo and wish him all
the best in his endeavours henceforth.”

For further information, contact:
Torbjörn Bjerke, President and CEO, Orexo AB
Tel: +46 (0) 708-661990
E-mail: torbjorn.bjerke@orexo.com (torbjorn.bjerke@orexo.com)

 

About Robin Wright
Robin has been Orexo's head of business development since 2008. A
chartered accountant, Robin has several years experience of
multi-national financial directorship, having been group finance
director of a group of 30 subsidiaries in seven countries for a private
equity fund from 1999 to 2004. He also has public company board
experience with four years on the board of US NASDAQ-quoted Hibernia
Foods plc, during which time the company reversed 18 consecutive
quarters of losses into a profit.

Robin's main commercial experience comes from over 20 years advising Big
Pharma and other international companies on corporate finance and
investment banking with some of the world's largest investment banks,
including Barclays and Citibank Salomon Smith Barney. He has completed
152 corporate M&A, financing, restructuring and licensing deals.

 

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. The company has four products on the market as
well as a broad project portfolio in late stages of development. Sales
and product development are mainly carried out through worldwide
partnership agreements with larger pharmaceutical companies. Orexo´s
most important product is for the management of breakthrough cancer
pain. It is based on Orexo's unique and patented sublingual tablet
technology in which a rapidly disintegrating tablet is placed under the
tongue and the active substance fentanyl is absorbed by the mucous
membrane. Currently AbstralTM is launched in most of Europe. Orexo has
its head office located in Uppsala, Sweden. More information can be
found at www.orexo.com.

  

Note:
This is information that Orexo AB (publ.) is required to disclose
pursuant to the Swedish Securities Markets Act. The information was
provided for public release on August 10, 2010 at 11:00 CET.